Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 471

1.

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Kalbasi A, Ribas A.

Clin Cancer Res. 2018 Apr 19. pii: clincanres.0698.2018. doi: 10.1158/1078-0432.CCR-18-0698. [Epub ahead of print]

PMID:
29674509
2.

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG.

Cancer Cell. 2018 Apr 3. pii: S1535-6108(18)30122-3. doi: 10.1016/j.ccell.2018.03.017. [Epub ahead of print]

PMID:
29657129
3.

Pitch-Matching Accuracy and Temporal Auditory Processing.

Fadel CBX, Ribas A, Lüders D, Fonseca VR, Cat MNL.

Int Arch Otorhinolaryngol. 2018 Apr;22(2):113-118. doi: 10.1055/s-0037-1603763. Epub 2017 Jun 13.

4.

Cancer immunotherapy using checkpoint blockade.

Ribas A, Wolchok JD.

Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22. Review.

PMID:
29567705
5.

Weed suppression greatly increased by plant diversity in intensively managed grasslands: A continental-scale experiment.

Connolly J, Sebastià MT, Kirwan L, Finn JA, Llurba R, Suter M, Collins RP, Porqueddu C, Helgadóttir Á, Baadshaug OH, Bélanger G, Black A, Brophy C, Čop J, Dalmannsdóttir S, Delgado I, Elgersma A, Fothergill M, Frankow-Lindberg BE, Ghesquiere A, Golinski P, Grieu P, Gustavsson AM, Höglind M, Huguenin-Elie O, Jørgensen M, Kadziuliene Z, Lunnan T, Nykanen-Kurki P, Ribas A, Taube F, Thumm U, De Vliegher A, Lüscher A.

J Appl Ecol. 2018 Mar;55(2):852-862. doi: 10.1111/1365-2664.12991. Epub 2017 Sep 27.

6.

Genetic mechanisms of immune evasion in colorectal cancer.

Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U.

Cancer Discov. 2018 Mar 6. pii: CD-17-1327. doi: 10.1158/2159-8290.CD-17-1327. [Epub ahead of print]

PMID:
29510987
7.

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC.

Science. 2018 Mar 2;359(6379):1037-1042. doi: 10.1126/science.aar3246.

8.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Feb 21. doi: 10.1097/CJI.0000000000000216. [Epub ahead of print]

PMID:
29470191
9.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. [Epub ahead of print]

10.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

11.

Molecular genetic diversity of Gongylonema neoplasticum (Fibiger & Ditlevsen, 1914) (Spirurida: Gongylonematidae) from rodents in Southeast Asia.

Setsuda A, Ribas A, Chaisiri K, Morand S, Chou M, Malbas F, Yunus M, Sato H.

Syst Parasitol. 2018 Mar;95(2-3):235-247. doi: 10.1007/s11230-018-9778-0. Epub 2018 Feb 14.

PMID:
29446034
12.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

13.

Global spread of helminth parasites at the human-domestic animal-wildlife interface.

Wells K, Gibson DI, Clark NJ, Ribas A, Morand S, McCallum HI.

Glob Chang Biol. 2018 Feb 13. doi: 10.1111/gcb.14064. [Epub ahead of print]

PMID:
29436086
14.

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.

Zhou J, Bethune MT, Malkova N, Sutherland AM, Comin-Anduix B, Su Y, Baltimore D, Ribas A, Heath JR.

PLoS One. 2018 Jan 23;13(1):e0191634. doi: 10.1371/journal.pone.0191634. eCollection 2018.

15.

Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

Nowicki TS, Hu-Lieskovan S, Ribas A.

Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303.

PMID:
29360728
16.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.

PMID:
29358500
17.

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF.

Cell. 2018 Feb 8;172(4):825-840.e18. doi: 10.1016/j.cell.2017.12.026. Epub 2018 Jan 11.

PMID:
29336888
18.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

PMID:
29320474
19.

Rational approach to the primary evaluation of thyroid disease in paediatrics. Full thyroid profile vs. thyroid-stimulating hormone and free thyroxine only.

Zaidman V, Lazzati JM, Maceiras M, Herzovich V, Pelanda M, Ribas A, Belgorosky A, Chaler EA.

Clin Chem Lab Med. 2018 Jan 5. pii: /j/cclm.ahead-of-print/cclm-2017-0962/cclm-2017-0962.xml. doi: 10.1515/cclm-2017-0962. [Epub ahead of print] No abstract available.

PMID:
29303772
20.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2017 Dec 28:JCO2017756270. doi: 10.1200/JCO.2017.75.6270. [Epub ahead of print]

PMID:
29283791
21.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
22.

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.

Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13679-13684. doi: 10.1073/pnas.1712064115. Epub 2017 Dec 11.

PMID:
29229836
23.

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J.

Pigment Cell Melanoma Res. 2017 Nov 20. doi: 10.1111/pcmr.12670. [Epub ahead of print]

PMID:
29156488
24.

Intestinal Parasitic Infections and Environmental Water Contamination in a Rural Village of Northern Lao PDR.

Ribas A, Jollivet C, Morand S, Thongmalayvong B, Somphavong S, Siew CC, Ting PJ, Suputtamongkol S, Saensombath V, Sanguankiat S, Tan BH, Paboriboune P, Akkhavong K, Chaisiri K.

Korean J Parasitol. 2017 Oct;55(5):523-532. doi: 10.3347/kjp.2017.55.5.523. Epub 2017 Oct 31.

25.

Evaluation of food intake and Fos expression in serotonergic neurons of raphe nuclei after intracerebroventricular injection of adrenaline in free-feeding rats.

Flores RA, da Silva ES, Ribas AS, Taschetto APD, Zampieri TT, Donato J Jr, Paschoalini MA.

Brain Res. 2018 Jan 1;1678:153-163. doi: 10.1016/j.brainres.2017.10.021. Epub 2017 Oct 24.

PMID:
29079504
26.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O.

Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398.

PMID:
29076950
27.

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A.

Leuk Lymphoma. 2017 Oct 23:1-12. doi: 10.1080/10428194.2017.1387905. [Epub ahead of print]

PMID:
29058502
28.

Perception of Noise Pollution in a Youth and Adults School in Curitiba-PR.

Borges Filho O, Ribas A, Gonçalves CGO, Lacerda ABM, Riesemberg R, Klagenberg K.

Int Arch Otorhinolaryngol. 2017 Oct;21(4):313-317. doi: 10.1055/s-0036-1597118. Epub 2016 Dec 19.

29.

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.

30.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA.

Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.

PMID:
28961848
31.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
32.

Endocrinopathies with use of cancer immunotherapies.

Villa NM, Farahmand A, Du L, Yeh MW, Smooke-Praw S, Ribas A, Chmielowski B, Cherry G, Leung AM.

Clin Endocrinol (Oxf). 2018 Feb;88(2):327-332. doi: 10.1111/cen.13483. Epub 2017 Oct 9.

PMID:
28941311
33.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.

PMID:
28886381
34.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

35.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
36.

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG.

Nat Commun. 2017 Aug 14;8(1):241. doi: 10.1038/s41467-017-00221-3.

37.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review.

PMID:
28756137
38.

Collaborative Care in Melanoma: The Essential Role of the Nurse
.

Kirkwood JM, Ribas A.

Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):4-6. doi: 10.1188/17.CJON.S4.4-6.

39.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.

PMID:
28729151
40.

Ultrastructural characters of the spermatozoon of the liver fluke Opisthorchis viverrini (Poirier, 1886) (Opisthorchiidae).

Miquel J, Świderski Z, Sripa B, Ribas A.

Parasitol Res. 2017 Sep;116(9):2499-2506. doi: 10.1007/s00436-017-5559-y. Epub 2017 Jul 19.

PMID:
28725936
41.

Draft Genome Sequences of Two Mycobacterium bovis Strains Isolated from Beef Cattle in Paraguay.

Sanabria L, Lagrave L, Nishibe C, Ribas ACA, Zumárraga MJ, Almeida NF, Araújo FR.

Genome Announc. 2017 Jul 13;5(28). pii: e00616-17. doi: 10.1128/genomeA.00616-17.

42.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

PMID:
28652246
43.

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK.

J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.

44.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
45.

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B.

J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0.

46.

Small intestinal peripheral nerve sheath tumour in a cat.

Ribas A, Miller R, Rasotto R.

JFMS Open Rep. 2017 Jun 6;3(1):2055116917710394. doi: 10.1177/2055116917710394. eCollection 2017 Jan-Jun.

47.

SnapShot: Immune Checkpoint Inhibitors.

Abril-Rodriguez G, Ribas A.

Cancer Cell. 2017 Jun 12;31(6):848-848.e1. doi: 10.1016/j.ccell.2017.05.010.

48.

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.

Wongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A.

Clin Cancer Res. 2017 Sep 1;23(17):5238-5245. doi: 10.1158/1078-0432.CCR-17-0172. Epub 2017 May 23.

PMID:
28536307
49.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A.

Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.

50.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.

Supplemental Content

Support Center